Atypical B Cells and Impaired SARS-CoV-2 Neutralization Following Heterologous Vaccination in the Elderly

Investigators showed that individuals 70 years or older who received a primary two-dose schedule with AZD1222 and booster third dose with mRNA vaccine achieve significantly lower neutralizing antibody responses against SARS-CoV-2 spike pseudotyped virus compared with those younger than 70 at 1 month post booster.